These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24798183)

  • 21. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 22. When are effective medications just too expensive?
    Mehta SJ; Asch DA
    Cleve Clin J Med; 2014 Mar; 81(3):173-5. PubMed ID: 24591472
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thousands of patients in England to get new hepatitis C drugs.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3222. PubMed ID: 26071408
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
    Sockalingam S; Sheehan K; Feld JJ; Shah H
    Am J Psychiatry; 2015 Jun; 172(6):512-6. PubMed ID: 26029803
    [No Abstract]   [Full Text] [Related]  

  • 26. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
    Berden FA; Kievit W; Baak LC; Bakker CM; Beuers U; Boucher CA; Brouwer JT; Burger DM; van Erpecum KJ; van Hoek B; Hoepelman AI; Honkoop P; Kerbert-Dreteler MJ; de Knegt RJ; Koek GH; van Nieuwkerk CM; van Soest H; Tan AC; Vrolijk JM; Drenth JP
    Neth J Med; 2014 Oct; 72(8):388-400. PubMed ID: 25387551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA approvals usher in the post-interferon era in HCV.
    Sheridan C
    Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting.
    Campos-Varela I; Peters MG; Terrault NA
    Clin Infect Dis; 2015 Jan; 60(1):108-16. PubMed ID: 25228702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs 2014, part 2.
    Hussar DA
    Nursing; 2014 Jul; 44(7):26-33; quiz 33-4. PubMed ID: 24905857
    [No Abstract]   [Full Text] [Related]  

  • 31. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Miller MH; Agarwal K; Austin A; Brown A; Barclay ST; Dundas P; Dusheiko GM; Foster GR; Fox R; Hayes PC; Leen C; Millson C; Ryder SD; Tait J; Ustianowski A; Dillon JF; ; ; ; ; ;
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1363-75. PubMed ID: 24754233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus: here comes all-oral treatment.
    Dugum M; O'Shea R
    Cleve Clin J Med; 2014 Mar; 81(3):159-72. PubMed ID: 24591471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simeprevir approved for hepatitis C virus infection.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(1):6. PubMed ID: 24352170
    [No Abstract]   [Full Text] [Related]  

  • 34. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlling hepatitis C with simeprevir.
    Dusheiko G
    Lancet Infect Dis; 2015 Jan; 15(1):2-4. PubMed ID: 25482331
    [No Abstract]   [Full Text] [Related]  

  • 36. Simeprevir (Olysio) for chronic hepatitis C.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):1-3. PubMed ID: 24419295
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
    Mishra P; Florian J; Qi K; Zeng W; Naeger LK; Donaldson E; Connelly S; O'Rear J; Price D; Murray J; Birnkrant D
    Gastroenterology; 2014 Dec; 147(6):1196-200. PubMed ID: 25449024
    [No Abstract]   [Full Text] [Related]  

  • 38. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What are the management issues for hepatitis C in dialysis patients?: natural history of hepatitis C in dialysis populations.
    Carrion AF; Martin P
    Semin Dial; 2014; 27(5):446-8. PubMed ID: 25204876
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
    Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.